MX352546B - Compuesto para la union de glicoproteina iib/iiia especifica a plaquetas y su uso para la formacion de imagenes de un trombo. - Google Patents

Compuesto para la union de glicoproteina iib/iiia especifica a plaquetas y su uso para la formacion de imagenes de un trombo.

Info

Publication number
MX352546B
MX352546B MX2014001784A MX2014001784A MX352546B MX 352546 B MX352546 B MX 352546B MX 2014001784 A MX2014001784 A MX 2014001784A MX 2014001784 A MX2014001784 A MX 2014001784A MX 352546 B MX352546 B MX 352546B
Authority
MX
Mexico
Prior art keywords
thrombi
imaging
iiia
binding
compounds
Prior art date
Application number
MX2014001784A
Other languages
English (en)
Other versions
MX2014001784A (es
Inventor
Berger Markus
Krüger Martin
Lohrke Jessica
Reinhardt Michael
Siebeneicher Holger
Original Assignee
Piramal Imaging Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Imaging Sa filed Critical Piramal Imaging Sa
Publication of MX2014001784A publication Critical patent/MX2014001784A/es
Publication of MX352546B publication Critical patent/MX352546B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06Ampoules or carpules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a compuestos novedosos que contienen flúor, métodos para su preparación, los intermediarios de la síntesis, su uso como agentes de diagnóstico, especialmente para la formación de imágenes de trombos. La invención se refiere a agentes de tomografía de emisión de positrones (PET) y reactivos precursores asociados, y métodos para producir tales agentes radioetiquetados para la formación de imágenes de trombos en un cuerpo de mamífero. Más particularmente, la invención se refiere a antagonistas de glicoproteina IIb/IIIa de unión específica, de alta afinidad, sin péptidos, pequeños para la formación de imágenes de trombos.
MX2014001784A 2011-08-17 2012-08-17 Compuesto para la union de glicoproteina iib/iiia especifica a plaquetas y su uso para la formacion de imagenes de un trombo. MX352546B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11075195 2011-08-17
PCT/EP2012/003583 WO2013023795A1 (en) 2011-08-17 2012-08-17 Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi

Publications (2)

Publication Number Publication Date
MX2014001784A MX2014001784A (es) 2014-05-01
MX352546B true MX352546B (es) 2017-11-29

Family

ID=46724333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014001784A MX352546B (es) 2011-08-17 2012-08-17 Compuesto para la union de glicoproteina iib/iiia especifica a plaquetas y su uso para la formacion de imagenes de un trombo.

Country Status (22)

Country Link
US (2) US9345793B2 (es)
EP (1) EP2744802B1 (es)
JP (2) JP6243335B2 (es)
KR (1) KR101948362B1 (es)
CN (1) CN103906743B (es)
AU (1) AU2012297137B2 (es)
BR (1) BR112014003366B1 (es)
CA (1) CA2845477C (es)
DK (1) DK2744802T3 (es)
ES (1) ES2621379T3 (es)
HK (1) HK1197064A1 (es)
HR (1) HRP20170464T1 (es)
IL (1) IL230854A (es)
MX (1) MX352546B (es)
MY (1) MY174617A (es)
NZ (1) NZ620635A (es)
PL (1) PL2744802T3 (es)
PT (1) PT2744802T (es)
RU (1) RU2597425C2 (es)
SG (1) SG2014011225A (es)
SI (1) SI2744802T1 (es)
WO (1) WO2013023795A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013023795A1 (en) * 2011-08-17 2013-02-21 Piramal Imaging Sa Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
KR101493571B1 (ko) * 2012-12-24 2015-02-13 (주)엘지하우시스 저방사 투명 적층체 및 이를 포함하는 건축 자재
JP6099045B2 (ja) * 2013-04-30 2017-03-22 国立大学法人京都大学 トリアゾロピリミジン誘導体化合物
JP5847140B2 (ja) * 2013-08-29 2016-01-20 国立大学法人東北大学 慢性血栓塞栓性肺高血圧症の検査方法
JP2017506633A (ja) * 2014-02-11 2017-03-09 バイエル・ファルマ・アクティエンゲゼルシャフト 血小板特異的糖タンパク質IIb/IIIaに結合するための金属キレート化合物
JP2015193545A (ja) * 2014-03-31 2015-11-05 国立大学法人京都大学 2−(3−ピリジニル)−1h−ベンズイミダゾール誘導体化合物、これを含む放射性医薬
CN105699563A (zh) * 2016-04-25 2016-06-22 广西壮族自治区梧州食品药品检验所 双波长高效液相色谱检测血栓通的方法
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20200253506A1 (en) 2016-12-14 2020-08-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
KR102548998B1 (ko) * 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5830856A (en) 1991-02-08 1998-11-03 Diatide, Inc. Radiolabeled compounds for thrombus imaging
US5508020A (en) 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
US6380215B1 (en) 1993-09-22 2002-04-30 Fujisawa Pharmaceutical Co., Ltd Beta-alanine derivative and a process for the preparation thereof
CA2215106A1 (en) 1995-03-17 1996-09-26 Fujisawa Pharmaceutical Co., Ltd. N-acylpiperidinylcarbonylaminocarboxylic acids and their use as glycoprotein iib/iiia antagonists and fibrinogen-blood platelets binding inhibitors
DE19540700A1 (de) 1995-11-02 1997-05-07 Daniels & Korff Gmbh Oberhemd mit Kragen
WO1997033869A1 (en) 1996-03-13 1997-09-18 Fujisawa Pharmaceutical Co., Ltd. N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist
ATE421952T1 (de) 1996-05-01 2009-02-15 Ortho Mcneil Pharm Inc Carboxamidderivate von pyrrolidin, piperidin und hexahydropiperizin für behandlung von thrombosen
US6066651A (en) 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders
US6028056A (en) 1998-02-06 2000-02-22 Diatide, Inc. Pharmaceutical compositions for imaging and treating thrombi
UA67832C2 (uk) 1999-03-22 2004-07-15 Орто-Макнейл Фармацевтикал, Інк. СПОСІБ ОТРИМАННЯ [S-(R<sup>*</sup>,S<sup>*</sup>)]-<font face="Symbol">b</font>-[[[1-[1-ОКСО-3-(4-ПІПЕРИДИНІЛ)ПРОПІЛ]-3-ПІПЕРИДИНІЛ]КАРБОНІЛ]АМІНО]-3-ПІРИДИНПРОПАНОВОЇ КИСЛОТИ ТА ЇЇ ПОХІДНИХ
WO2005079863A1 (ja) * 2004-02-25 2005-09-01 Astellas Pharma Inc. 血栓造影剤
EP2297070A2 (en) * 2008-07-03 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Compounds and processes for production of radiopharmaceuticals
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
WO2013023795A1 (en) * 2011-08-17 2013-02-21 Piramal Imaging Sa Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi

Also Published As

Publication number Publication date
JP2017075159A (ja) 2017-04-20
PT2744802T (pt) 2017-03-15
CA2845477C (en) 2019-04-23
US20160137629A1 (en) 2016-05-19
RU2014109853A (ru) 2015-09-27
MX2014001784A (es) 2014-05-01
HRP20170464T1 (hr) 2017-05-19
BR112014003366B1 (pt) 2020-08-04
WO2013023795A1 (en) 2013-02-21
NZ620635A (en) 2015-09-25
IL230854A (en) 2015-07-30
JP2014525924A (ja) 2014-10-02
CN103906743A (zh) 2014-07-02
CN103906743B (zh) 2016-12-28
EP2744802B1 (en) 2017-01-04
SG2014011225A (en) 2014-06-27
AU2012297137A1 (en) 2014-03-27
MY174617A (en) 2020-05-01
JP6243335B2 (ja) 2017-12-06
PL2744802T3 (pl) 2017-07-31
RU2597425C2 (ru) 2016-09-10
BR112014003366A2 (pt) 2017-03-01
ES2621379T3 (es) 2017-07-03
HK1197064A1 (en) 2015-01-02
CA2845477A1 (en) 2013-02-21
US9744252B2 (en) 2017-08-29
EP2744802A1 (en) 2014-06-25
KR101948362B1 (ko) 2019-02-14
DK2744802T3 (en) 2017-04-03
US20140314669A1 (en) 2014-10-23
US9345793B2 (en) 2016-05-24
AU2012297137B2 (en) 2017-03-02
SI2744802T1 (sl) 2017-05-31
IL230854A0 (en) 2014-03-31
KR20140085426A (ko) 2014-07-07

Similar Documents

Publication Publication Date Title
MX2014001784A (es) Compuesto para la union de glicoproteina iib/iiia especifica a plaquetas y su uso para la formacion de imagenes de un trombo.
JP2011105738A5 (es)
MY174025A (en) Azole silane compound, surface treatment solution, surface treatment method, and use thereof
MX2010002902A (es) Pirimidinas anti-infecciosas y usos de las mismas.
HK1118713A1 (en) Diagnostic compounds
PH12013500365A1 (en) Anti-infective agents and uses thereof
MX347515B (es) Agentes que se unen al receptor encrespado y usos de los mismos.
MY172806A (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
MX2013012793A (es) Aminoacidos radiomarcados para imagen de diagnostico.
JO3154B1 (ar) عوامل مضادة لـ trpv4
BR112015004029A2 (pt) Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo
FR2959962B3 (fr) Plaque pour la fabrication de chariots pour avion
BR112015015368A2 (pt) composições de absorventes de dejetos de animais revestidas debaixa densidade
WO2012116196A3 (en) Substituted lactosyl compounds and use thereof for cellular imaging and therapy
PH12016500683A1 (en) Synthetic route to 2`-deoxy-2`,2`-difluorotetrahydrouridines
MX362858B (es) Proceso para la preparacion de pemetrexed y sal de lisina del mismo.
AU2010332841A8 (en) Prostate specific membrane antigen inhibitors
MX340487B (es) Compuestos para usarse en la formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central.
MX2013012795A (es) Procursores novedosos de derivados de glutamato.
WO2012040133A3 (en) Novel precursors of radiolabelled choline analog compounds
MX356258B (es) Agente de contraste para obtener imágenes de la perfusión miocárdica.
IN2014DN06805A (es)
GB201110767D0 (en) Infection imaging
MX2013010781A (es) Compuestos para usarse en formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central.
PH12014501760B1 (en) Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro[5.5]undecanes

Legal Events

Date Code Title Description
FG Grant or registration